Artiva Biotherapeutics Board Member Shows Long-Term Commitment with Option Grant

Rhea-AI Filing Summary

Artiva Biotherapeutics Director Gines Diego Miralles received a stock option grant on June 24, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:

• Grant of 13,750 stock options to purchase common stock
• Exercise price set at $1.61 per share
• Options expire on June 23, 2035
• Full vesting occurs on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting

The filing was executed by Neha Krishnamohan as attorney-in-fact on June 26, 2025. This transaction represents a standard director compensation equity grant, with Miralles holding direct ownership of these derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miralles Gines Diego

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	13,750	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miralles Gines Diego

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$1.61	06/24/2025		A		13,750		(1)	06/23/2035	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

	/s/ Neha Krishnamohan, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to ARTV's director Gines Diego Miralles on June 24, 2025?

Director Gines Diego Miralles was granted 13,750 stock options with an exercise price of $1.61 per share. These options were granted on June 24, 2025, and will expire on June 23, 2035.

When do the stock options granted to ARTV's director Miralles vest?

According to the filing, the stock options will vest in full on the earlier of either June 24, 2026, or the date of Artiva Biotherapeutics' 2026 annual stockholder meeting.

What is the exercise price of ARTV director Miralles' stock options granted in June 2025?

The exercise price of the director stock options (Right to Buy) granted to Gines Diego Miralles is $1.61 per share.

How many ARTV shares could Director Miralles acquire through the June 2025 stock option grant?

Through this stock option grant, Director Miralles could acquire 13,750 shares of ARTV common stock upon exercise of the options.

When do the stock options granted to ARTV's Director Miralles expire?

The stock options granted to Director Miralles expire on June 23, 2035, giving him a 10-year period to exercise the options from the grant date.